Filament Health has commenced the largest production run in its history of its standardized, patented PEX010 botanical psilocybin drug candidate, introducing a new 0.5 mg dose alongside its existing 1, 5 and 25 mg strengths to deliver the widest standardized dosing range available from any natural psilocybin drug candidate, every strength produced using the same proprietary extraction and stabilization methods.
Toronto, Ontario--(Newsfile Corp. - July 8, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010.
The Company is pleased to announce that Filament has commenced the largest manufacturing run in its history of PEX010, its standardized, patented botanical psilocybin drug candidate. The expanded production run is designed to meet sustained global demand from academic and clinical research institutions and to broaden the range of standardized doses available to investigators worldwide.
As part of this run, Filament is introducing a new 0.5 mg dose alongside its existing 1, 5 and 25 mg strengths, giving researchers a standardized range of 0.5, 1, 5 and 25 mg from a single drug candidate, from sub-hallucinogenic microdosing through to full therapeutic doses. Standardized natural psilocybin offerings elsewhere have generally been confined to a narrow band of mid-range doses, whereas every PEX010 strength is drawn from the same drug product and produced to the same specification, so that a 0.5 mg dose and a 25 mg dose share an identical composition, purity, and stability profile, differing only in strength rather than in batch or method.
PEX010 is produced using Filament's proprietary extraction, purification, and stabilization methods, which deliver a potent yet standardized and patented botanical drug product with consistent composition across every dose, every study, and every research site. That consistency is protected by a broad international patent portfolio and backed by a demonstrated 36-month shelf life. PEX010 offers reproducibility at scale, a composition that does not drift from one production run to the next, allowing investigators to attribute their findings to the compound itself rather than to batch-to-batch variation.